[go: up one dir, main page]

AU1992592A - Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors - Google Patents

Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Info

Publication number
AU1992592A
AU1992592A AU19925/92A AU1992592A AU1992592A AU 1992592 A AU1992592 A AU 1992592A AU 19925/92 A AU19925/92 A AU 19925/92A AU 1992592 A AU1992592 A AU 1992592A AU 1992592 A AU1992592 A AU 1992592A
Authority
AU
Australia
Prior art keywords
drug
treatment
type
monoamine oxidase
withdrawal symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19925/92A
Inventor
George W. Belenduik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Pharmavene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmavene Inc filed Critical Pharmavene Inc
Publication of AU1992592A publication Critical patent/AU1992592A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU19925/92A 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors Abandoned AU1992592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70508591A 1991-05-24 1991-05-24
US705085 1991-05-24

Publications (1)

Publication Number Publication Date
AU1992592A true AU1992592A (en) 1993-01-08

Family

ID=24831978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19925/92A Abandoned AU1992592A (en) 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Country Status (2)

Country Link
AU (1) AU1992592A (en)
WO (1) WO1992021333A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713087B1 (en) * 1993-11-30 1996-02-23 Saurat Jean Hilaire Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.
DE4428444A1 (en) * 1994-08-11 1996-02-15 Dresden Arzneimittel Use of selegiline for the treatment of epileptic disorders
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
WO1996024346A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
AU718096C (en) 1995-06-07 2001-11-22 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19746191C2 (en) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
WO2003039525A1 (en) * 2001-11-05 2003-05-15 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
KR20120041739A (en) 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 Hapten-carrier conjugates and uses thereof
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS AND DISEASES
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
DE102006038719A1 (en) 2006-08-18 2008-02-21 Tesa Ag Pressure-sensitive adhesive strips for moisture-resistant, removable adhesive bonds
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
HUE044221T2 (en) 2010-02-03 2019-10-28 Pharma Two B Ltd Extended release formulations of rasagiline and uses thereof
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
DK2545047T3 (en) 2010-03-10 2014-07-28 Probiodrug Ag Heterocyclic Inhibitors of Glutaminyl Cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
PT2611440T (en) 2010-09-01 2017-04-26 Tonix Pharmaceuticals Inc Treatment for cocaine addiction
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Also Published As

Publication number Publication date
WO1992021333A2 (en) 1992-12-10
WO1992021333A3 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
AU1992592A (en) Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
WO1994012165A3 (en) Enzyme inhibitors
AU2804489A (en) New device and new method for drug administration
NZ335146A (en) N-(N'-substituted glycyl)-2-cyanopyrrolidine derivatives and medicaments
AU6042696A (en) Drug delivery catheters and methods of use
AU2005388A (en) Method and device for vapor sterilization of articles having lumens
AU4342689A (en) Cryoablation catheter and method of performing cryoablation
AU4932190A (en) Oxygen delignification and enzyme treatment
AU1007788A (en) Proximal manifold and adapter
EP0428585A4 (en) Novel method of administering aspirin and dosage forms containing same
AU4263789A (en) Antimalarial compositions and methods of treatment using quinidine, artemisinine and its derivatives
AU4238693A (en) Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
AU1279788A (en) Compounds and treatment
AU6867787A (en) Process and kit for drug detection
AU1846488A (en) Analgesic and anti-inflammatory thiourea derivatives
NO991551D0 (en) Use of tetrahydrobenz (cd) indole-6-carboxamides in the preparation of drugs for the prevention of emesis and treatment of sexual dysfunction
AU1029588A (en) Synergistic combination of azelastine and theophylline or azelastine and beta-mimetics
AU4426289A (en) Methods for interfering with hiv multiplication and composition for the treatment of aids
AU3075692A (en) Method of producing and treatment with tablet composition
NZ237040A (en) Tricyclic cholinesterase inhibitors and medicaments thereof
AU1956092A (en) Pharmaceutical agent for treatment of withdrawal symptoms
HUP9901990A2 (en) Furan- and thiophene derivatives having inhibitor effect on the replication of hiv-1 and hiv-1 mutants, and medicaments containing the same
AU4006989A (en) Method of inhibiting the spread of disease and infection in structures
AU2143488A (en) Use of a compound for the treatment of sleep disorders and depression
AU1900488A (en) Device and composition for treatment of gums